At the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision oncology with a robust portfolio of theranostics-enabled solutions aimed at elevating both clinical decision-making and operational efficiency. Among the key innovations making their debut is LesionID™ Pro from GE HealthCare’s MIM Software – featuring automated zero-click pre-processing, an AI-driven advancement designed to support therapy monitoring and enhance diagnostic accuracy.
Cancer continues to be a leading global health challenge, contributing to more than 10 million deaths annually. As the demand grows for more personalized, efficient care models, theranostics – a fusion of targeted diagnostics and therapeutics – is emerging as a powerful tool to address this burden. By leveraging molecular imaging and tailored radiopharmaceuticals, theranostics enables a patient-centric approach to cancer detection, monitoring, and treatment.
“Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,” shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine and Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. “With tools like GE HealthCare’s Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry-ultimately helping improve outcomes for our patients. This is precision care in action, and it’s making a real difference in patients’ lives.”
Also Read: Kontakt.io Launches Temperature Monitoring Solution for Critical Healthcare Supplies
Empowering Theranostics Through AI and Molecular Imaging
Molecular imaging technologies such as PET (positron emission tomography) and SPECT (single photon emission computed tomography) form the foundation of theranostic practices. These modalities offer deep, patient-specific insights critical for guiding treatment strategies and monitoring progress. Yet, extracting comprehensive insights like whole-body tumor burden has traditionally required labor-intensive, manual workflows—posing significant clinical and operational bottlenecks.
Addressing these challenges, LesionID Pro from MIM Software introduces AI-powered zero-click pre-processing that automates time-consuming steps such as lesion segmentation, physiological uptake removal, and image registration. This innovation provides clinicians with rapid access to whole-body tumor burden metrics—eliminating hours of manual analysis and supporting timely, informed treatment decisions.
The latest version of LesionID Pro also includes major algorithmic enhancements that deliver more precise whole-body tumor volume measurements for physician review. The software’s intuitive interface, developed in collaboration with leading theranostics experts, is built to streamline workflows and accelerate time-to-report—making advanced tumor burden analysis a practical reality in routine clinical settings.
“At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,” shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. “We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient’s entire care journey – from the imaging equipment needed for a noninvasive look at a patient’s anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.”